ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer

Cancer Cell

Volumn 29, Issue 6, 2016, Pages 874-888

  Napoli, Marco ^a   Venkatanarayan, Avinashnarayan ^a,b   Raulji, Payal ^a   Meyers, Brooke A ^a   Norton, William ^a   Mangala, Lingegowda S ^a   Sood, Anil K ^a   Rodriguez Aguayo, Cristian ^a   Lopez Berestein, Gabriel ^a   Vin, Harina ^c   Duvic, Madeleine ^c   Tetzlaff, Michael B ^a,c   Curry, Jonathan L ^a,c   Rook, Alain H ^d   Abbas, Hussein A ^a   Coarfa, Cristian ^e   Gunaratne, Preethi H ^f   Tsai, Kenneth Y ^a,b,c   Flores, Elsa R ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c University of Texas Health Science Center at Houston   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AR 42; DELTA NP63 PROTEIN; DGCR8 PROTEIN; FBW7 PROTEIN; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; LET 7D; MICRORNA; MICRORNA 128; MICRORNA 200A; MICRORNA 200C; MICRORNA 31; PANOBINOSTAT; PROTEIN; QUISINOSTAT; RNA PRECURSOR; SB 939; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; DGCR8 PROTEIN, HUMAN; MIRN128 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; MOLECULAR LIBRARY; PROTEIN P53; RNA BINDING PROTEIN; TP53 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; SQUAMOUS CELL CARCINOMA; STEADY STATE; TUMOR REGRESSION; TUMOR RESISTANCE; TUMOR VOLUME; ADMINISTRATION AND DOSAGE; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULAR LIBRARY; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA; MICE; MICRORNAS; RNA-BINDING PROTEINS; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979645235     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.04.016     Document Type: Article

References (54)

1. Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M.B., Guzzardo, V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137 (2009), 87–98.
2. Babiarz, J.E., Ruby, J.G., Wang, Y., Bartel, D.P., Blelloch, R., Mouse ES cells express endogenous shRNAs, siRNAs, and other microprocessor-independent, Dicer-dependent small RNAs. Genes Dev. 22 (2008), 2773–2785.
3. Babiarz, J.E., Hsu, R., Melton, C., Thomas, M., Ullian, E.M., Blelloch, R., A role for noncanonical microRNAs in the mammalian brain revealed by phenotypic differences in Dgcr8 versus Dicer1 knockouts and small RNA sequencing. RNA 17 (2011), 1489–1501.
4. Bose, P., Dai, Y., Grant, S., Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol. Ther. 143 (2014), 323–336.
5. Chakravarti, D., Su, X., Cho, M.S., Bui, N.H., Coarfa, C., Venkatanarayan, A., Benham, A.L., Flores Gonzalez, R.E., Alana, J., Xiao, W., et al. Induced multipotency in adult keratinocytes through down-regulation of DeltaNp63 or DGCR8. Proc. Natl. Acad. Sci. USA 111 (2014), E572–E581.
6. Chen, M.C., Chen, C.H., Chuang, H.C., Kulp, S.K., Teng, C.M., Chen, C.S., Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology 53 (2011), 148–159.
7. Creighton, C.J., Nagaraja, A.K., Hanash, S.M., Matzuk, M.M., Gunaratne, P.H., A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 14 (2008), 2290–2296.
8. Davis, M.P., Abreu-Goodger, C., van Dongen, S., Lu, D., Tate, P.H., Bartonicek, N., Kutter, C., Liu, P., Skarnes, W.C., Enright, A.J., Dunham, I., Large-scale identification of microRNA targets in murine Dgcr8-deficient embryonic stem cell lines. PLoS One, 7, 2012, e41762.
9. Davis, R.J., Welcker, M., Clurman, B.E., Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 26 (2014), 455–464.
10. Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., Jacks, T., p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002), 560–564.
11. Galli, F., Rossi, M., D'Alessandra, Y., De Simone, M., Lopardo, T., Haupt, Y., Alsheich-Bartok, O., Anzi, S., Shaulian, E., Calabro, V., et al. MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J. Cell Sci. 123 (2010), 2423–2433.
12. Girardini, J.E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., Quinlan, P., Thompson, A., et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20 (2011), 79–91.
13. Halder, J., Kamat, A.A., Landen, C.N. Jr., Han, L.Y., Lutgendorf, S.K., Lin, Y.G., Merritt, W.M., Jennings, N.B., Chavez-Reyes, A., Coleman, R.L., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12 (2006), 4916–4924.
14. Inoue, K., Fry, E.A., Alterations of p63 and p73 in human cancers. Subcell. Biochem. 85 (2014), 17–40.
15. Jung, Y.S., Qian, Y., Yan, W., Chen, X., Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. J. Invest. Dermatol. 133 (2013), 1178–1187.
16. Karni-Schmidt, O., Castillo-Martin, M., Shen, T.H., Gladoun, N., Domingo-Domenech, J., Sanchez-Carbayo, M., Li, Y., Lowe, S., Prives, C., Cordon-Cardo, C., Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol. 178 (2011), 1350–1360.
17. Kolenda, T., Przybyla, W., Teresiak, A., Mackiewicz, A., Lamperska, K.M., The mystery of let-7d—a small RNA with great power. Contemp. Oncol. (Pozn.) 18 (2014), 293–301.
18. Li, Y., Zhou, Z., Chen, C., WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 15 (2008), 1941–1951.
19. Li, M., Fu, W., Wo, L., Shu, X., Liu, F., Li, C., miR-128 and its target genes in tumorigenesis and metastasis. Exp. Cell Res. 319 (2013), 3059–3064.
20. Liu, B., Liu, M., Wang, J., Zhang, X., Wang, X., Wang, P., Wang, H., Li, W., Wang, Y., DICER-dependent biogenesis of let-7 miRNAs affects human cell response to DNA damage via targeting p21/p27. Nucleic Acids Res. 43 (2015), 1626–1636.
21. Mangala, L.S., Han, H.D., Lopez-Berestein, G., Sood, A.K., Liposomal siRNA for ovarian cancer. Methods Mol. Biol. 555 (2009), 29–42.
22. Marchini, S., Marabese, M., Marrazzo, E., Mariani, P., Cattaneo, D., Fossati, R., Compagnoni, A., Fruscio, R., Lissoni, A.A., Broggini, M., DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 19 (2008), 501–507.
23. Muller, P.A., Vousden, K.H., Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25 (2014), 304–317.
24. Muller, P.A., Caswell, P.T., Doyle, B., Iwanicki, M.P., Tan, E.H., Karim, S., Lukashchuk, N., Gillespie, D.A., Ludwig, R.L., Gosselin, P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139 (2009), 1327–1341.
25. Napoli, M., Flores, E.R., The family that eats together stays together: new p53 family transcriptional targets in autophagy. Genes Dev. 27 (2013), 971–974.
26. Nuovo, G.J., Garofalo, M., Valeri, N., Roulstone, V., Volinia, S., Cohn, D.E., Phelps, M., Harrington, K.J., Vile, R., Melcher, A., et al. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod. Pathol. 25 (2012), 1333–1344.
27. Ocker, M., Schneider-Stock, R., Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 39 (2007), 1367–1374.
28. Orzol, P., Holcakova, J., Nekulova, M., Nenutil, R., Vojtesek, B., Coates, P.J., The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol. Histopathol. 30 (2014), 503–521.
29. Ozcan, G., Ozpolat, B., Coleman, R.L., Sood, A.K., Lopez-Berestein, G., Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 87 (2015), 108–119.
30. Park, Y.W., Younes, M.N., Jasser, S.A., Yigitbasi, O.G., Zhou, G., Bucana, C.D., Bekele, B.N., Myers, J.N., AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin. Cancer Res. 11 (2005), 1963–1973.
31. Ramsey, M.R., He, L., Forster, N., Ory, B., Ellisen, L.W., Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 71 (2011), 4373–4379.
32. Restelli, M., Lopardo, T., Lo Iacono, N., Garaffo, G., Conte, D., Rustighi, A., Napoli, M., Del Sal, G., Perez-Morga, D., Costanzo, A., et al. DLX5, FGF8 and the Pin1 isomerase control DeltaNp63alpha protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. Hum. Mol. Genet. 23 (2014), 3830–3842.
33. Rossi, M., Aqeilan, R.I., Neale, M., Candi, E., Salomoni, P., Knight, R.A., Croce, C.M., Melino, G., The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl. Acad. Sci. USA 103 (2006), 12753–12758.
34. Rossi, M., De Simone, M., Pollice, A., Santoro, R., La Mantia, G., Guerrini, L., Calabro, V., Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle 5 (2006), 1816–1822.
35. Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K.M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R., Pili, R., Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One, 7, 2012, e30815.
36. Shen, L., Chen, X.D., Zhang, Y.H., MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol. 35 (2014), 2069–2074.
37. Su, X., Chakravarti, D., Cho, M.S., Liu, L., Gi, Y.J., Lin, Y.L., Leung, M.L., El-Naggar, A., Creighton, C.J., Suraokar, M.B., et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467 (2010), 986–990.
38. Su, X., Chakravarti, D., Flores, E.R., p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat. Rev. Cancer 13 (2013), 136–143.
39. Sweet, M.J., Shakespear, M.R., Kamal, N.A., Fairlie, D.P., HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol. Cell Biol. 90 (2012), 14–22.
40. van Kouwenhove, M., Kedde, M., Agami, R., MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat. Rev. Cancer 11 (2011), 644–656.
41. Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S.K., Ramirez, M.S., Lee, J., Kingsley, C.V., et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 517 (2015), 626–630.
42. Villagra, A., Sotomayor, E.M., Seto, E., Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29 (2010), 157–173.
43. Volinia, S., Galasso, M., Sana, M.E., Wise, T.F., Palatini, J., Huebner, K., Croce, C.M., Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. USA 109 (2012), 3024–3029.
44. Wada, T., Kikuchi, J., Furukawa, Y., Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep. 13 (2012), 142–149.
45. West, A.C., Johnstone, R.W., New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124 (2014), 30–39.
46. Yamaguchi, H., Woods, N.T., Piluso, L.G., Lee, H.H., Chen, J., Bhalla, K.N., Monteiro, A., Liu, X., Hung, M.C., Wang, H.G., p53 acetylation is crucial for its transcription-independent proapoptotic functions. J. Biol. Chem. 284 (2009), 11171–11183.
47. Yan, W., Chen, X., Zhang, Y., Zhang, J., Jung, Y.S., Chen, X., Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of DeltaNp63 protein. J. Biol. Chem. 288 (2013), 2907–2913.
48. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M.D., Dotsch, V., Andrews, N.C., Caput, D., McKeon, F., p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998), 305–316.
49. Yeh, J.E., Toniolo, P.A., Frank, D.A., Targeting transcription factors: promising new strategies for cancer therapy. Curr. Opin. Oncol. 25 (2013), 652–658.
50. Yi, R., Pasolli, H.A., Landthaler, M., Hafner, M., Ojo, T., Sheridan, R., Sander, C., O'Carroll, D., Stoffel, M., Tuschl, T., Fuchs, E., DGCR8-dependent microRNA biogenesis is essential for skin development. Proc. Natl. Acad. Sci. USA 106 (2009), 498–502.
51. Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., Anderson, D.G., Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15 (2014), 541–555.
52. Yu, D., Green, B., Marrone, A., Guo, Y., Kadlubar, S., Lin, D., Fuscoe, J., Pogribny, I., Ning, B., Suppression of CYP2C9 by MicroRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci. Rep., 5, 2015, 8534.
53. Zhang, C., Richon, V., Ni, X., Talpur, R., Duvic, M., Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 125 (2005), 1045–1052.
54. Zhang, J., Xu, E., Chen, X., TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function. J. Biol. Chem. 288 (2013), 7727–7737.